News
6h
TipRanks on MSNGSK Expands Share Buyback Programme with New Purchase
GlaxoSmithKline has announced the purchase of 306,478 of its own ordinary shares as part of its ongoing buyback programme. This transaction, executed through Merrill Lynch International, is part of a ...
Arab Finance: GlaxoSmithKline Egypt (GSK–Egypt) logged consolidated net profits for controlling interest of EGP 65.060 ...
In exchange, Hengrui will receive $500m in upfront fees and will be eligible for approximately $12bn in development, ...
British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...
GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...
GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...
Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...
1d
GlobalData on MSNEli Lilly and GSK drive South Korea’s drug licensing activity
South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.
The pharma giant will also receive a 1% royalty on future U.S. sales of influenza, Covid-19 and other related combination ...
Shares of GSK PLC GSK slid 3.04% to £14.18 Thursday, on what proved to be an all-around rough trading session for the stock ...
With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking to its projection to generate sales of more than 40 billion pounds sterling ...
SALES FORECAST: The U.K. pharmaceutical company is expected to report sales of 7.8 billion pounds ($10.42 billion), according to consensus estimates compiled by the company. For last year's second ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results